Samsung Ventures makes investment in preclinical-stage biopharmaceutical company BrickBio

三星风险投资于临床前阶段的生物制药公司BrickBio

Proceeds will be used to support further development and advancement of BrickBio's protein engineering technology and preclinical assets

收益将用于支持BrickBio蛋白质工程技术和临床前资产的进一步发展和进步

INCHEON, Korea and WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code..

韩国仁川和马萨诸塞州沃尔瑟姆，2024年3月18日/PRNewswire/--三星生命科学基金，由三星生物制品（KRX:207940.KS）、三星生物科技（Samsung Bioepis）和三星C&T（KRX:028260.KS）共同创建，由三星风险投资管理，BrickBio，Inc.宣布三星对BrickBio的投资，一家临床前阶段的生物制药公司专注于使用扩展的遗传密码开发精密生物制剂。

The latest investment reflects Samsung's commitment to discover and explore new opportunities in biopharmaceuticals to address unmet therapeutic needs. Samsung affiliates will work with BrickBio to evaluate, manufacture, and develop advanced molecules and therapies using BrickBio's proprietary protein engineering technology for antibody-drug conjugates (ADCs), AAV gene therapy, and other modalities.

这项最新投资反映了三星致力于发现和探索生物制药领域的新机遇，以满足未满足的治疗需求。三星附属公司将与BrickBio合作，使用BrickBio专有的抗体-药物偶联物（ADC），AAV基因治疗和其他方式的蛋白质工程技术，评估，制造和开发先进的分子和疗法。

BrickBio's technology uses an expanded genetic code to incorporate synthetic amino acids into proteins, all completed within a living cell. These synthetic amino acids enable the creation of precision biologics, an exciting new class of therapeutics with broad application and potential..

BrickBio的技术使用扩展的遗传密码将合成氨基酸整合到蛋白质中，所有这些都在活细胞内完成。这些合成氨基酸使精密生物制剂成为可能，这是一类具有广泛应用和潜力的令人兴奋的新疗法。

'We're pleased to receive this support from Samsung, as well as the recognition of the potential for our advanced protein engineering technology to provide novel solutions for challenging medical conditions,' said John Boyce, the Chief Executive Officer and Co-Founder of BrickBio and Tiger Gene. 'We look forward to using these proceeds to further our efforts in advancing our ADC candidates toward the clinic.'.

BrickBio和Tiger Gene首席执行官兼联合创始人约翰·博伊斯（JohnBoyce）说，我们很高兴得到三星的支持，也很高兴认识到我们先进的蛋白质工程技术有潜力为具有挑战性的医疗条件提供新的解决方案我们期待着利用这些收益进一步推动我们的ADC候选人走向诊所。”

'BrickBio's robust expanded genetic code in mammalian cells offer the potential to create molecules and therapies to address unmet needs,' said Ho Sung Cho, the Executive Vice President and Head of Early Research and Development of Samsung Bioepis.

三星Bioepis执行副总裁兼早期研发负责人Ho Sung Cho说，“BrickBio在哺乳动物细胞中强大的扩展遗传密码提供了创造分子和疗法以满足未满足需求的潜力。”

BrickBio's innovation engine continues to expand the preclinical pipeline by discovering new and valuable programs that take full advantage of its technologies. These novel programs have the potential to address a wide range of diseases with new or improved mechanisms of action, providing the company with a rich set of programs to develop internally and/or in partnership with leading pharmaceutical companies..

BrickBio的创新引擎通过发现充分利用其技术的新的有价值的项目，继续扩大临床前管道。这些新颖的计划有可能通过新的或改进的行动机制来解决各种疾病，为公司内部和/或与领先的制药公司合作开发一套丰富的计划。

About BrickBio, Inc.

关于BrickBio, Inc.

BrickBio Inc., a Boston-based biotechnology company, empowers next-generation unnatural amino acid coupled protein conjugation with its site-specific and site-selective platform. The platform technology spans prokaryotic and eukaryotic expression systems, enabling the development of unique biologics and protein therapeutics with enhanced characteristics, including improvements to half-life, dosage and efficacy.

波士顿生物技术公司BrickBio Inc.通过其位点特异性和位点选择性平台，实现了下一代非天然氨基酸偶联蛋白偶联。该平台技术跨越原核和真核表达系统，能够开发具有增强特性的独特生物制剂和蛋白质治疗剂，包括改善半衰期，剂量和功效。

With the broadest toolkit of bioconjugation handles, BrickBio can optimize any conjugate and is uniquely situated to push the frontier of biologics with the selective modification of multiple distinct sites on a single protein. BrickBio is expanding its therapeutic programs, including ADCs, bispecific conjugates and novel scaffolds..

凭借最广泛的生物缀合手柄工具包，BrickBio可以优化任何缀合物，并且具有独特的位置，可以通过选择性修饰单个蛋白质上的多个不同位点来推动生物制剂的前沿。BrickBio正在扩大其治疗计划，包括ADC，双特异性结合物和新型支架。

For more information, please visit www.brickbio.com.

有关更多信息，请访问www.brickbio.com。

About Samsung Ventures

关于Samsung Ventures

Samsung Venture Investment Corporation was established to promote promising small and medium-sized companies engaging in the development of new technologies. Our collaboration is based on managerial know-how and trust, and actively investing in future-oriented businesses based on new and innovative technologies that are expected to serve as new growth engines.

三星风险投资公司（Samsung Venture Investment Corporation）的成立是为了促进有前途的中小企业参与新技术的开发。我们的合作基于管理技能和信任，并积极投资于基于新的创新技术的面向未来的业务，这些技术有望成为新的增长引擎。